<DOC>
	<DOCNO>NCT01387802</DOCNO>
	<brief_summary>The current study ass real - life effectiveness adalimumab management Ankylosing Spondylitis ( AS ) emphasis prevention management extra-articular manifestation .</brief_summary>
	<brief_title>Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Effectiveness Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Anti-Inflammatory Agents , Non-Steroidal</mesh_term>
	<criteria>Adult &gt; = 18 year old ; Has provide write informed consent allow use data study provide permission contact study personnel ; Active Ankylosing Spondylitis per judgment treat physician ; Inadequate response non tolerant current NSAID ( Nonsteroidal AntiInflammatory Drug ) DMARD ( DiseaseModifying Anti Rheumatic Drug ) base treatment AS Currently participate another prospective study include control clinical trial observational study ; Patient sign inform consent ; Stable disease adequate tolerance response current treatment change treatment indicate ; Previous treatment antiTNF ( Tumor Necrosis Factor ) biologic agent ; Presence condition , opinion treat physician , prohibits patient participate study obscures assessment treatment AS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Assessing Effectiveness Ankylosing Spondylitis</keyword>
</DOC>